Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Astrocytoma, Grade IV

lutetium has been researched along with Astrocytoma, Grade IV in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Jacobs, N; More, S; Naiker, T; Oompie, F; Prasad, V1
ArunRaj, ST; Bal, C; Ballal, S; Damle, NA; Garg, A; Gupta, S; Haresh, KP; Kumar, A; Tripathi, M; Yadav, MP1
Chen, Y; Chong, HS; Kang, CS; Kweon, J; Lee, H; Lewis, MR; Liu, D; Sun, X1
Dorn, HC; Fatouros, PP; Fuller, CE; Shultz, MD; Wilson, JD; Zhang, J1
Bulte, JW1
Blomquist, E; Bruskin, A; Carlsson, J; Gedda, L; Orlova, A; Sundberg, AL; Tolmachev, V1

Other Studies

6 other study(ies) available for lutetium and Astrocytoma, Grade IV

ArticleYear
Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma.
    Clinical nuclear medicine, 2023, May-01, Volume: 48, Issue:5

    Topics: Adult; Dipeptides; Glioblastoma; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Recurrence, Local; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome

2023
177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:12

    Topics: Adult; Gallium Isotopes; Gallium Radioisotopes; Glioblastoma; Humans; Lutetium; Male; Membrane Glycoproteins; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radioisotopes; Recurrence

2020
Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.
    Nuclear medicine and biology, 2015, Volume: 42, Issue:3

    Topics: Animals; Cell Line, Tumor; Chelating Agents; Chemistry Techniques, Synthetic; Drug Stability; Glioblastoma; Heterocyclic Compounds; Humans; Isotope Labeling; Kinetics; Lutetium; Mice; Molecular Targeted Therapy; Oligopeptides; Tissue Distribution; Yttrium Radioisotopes

2015
Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.
    Radiology, 2011, Volume: 261, Issue:1

    Topics: Animals; Brachytherapy; Brain Neoplasms; Coordination Complexes; Disease Models, Animal; Female; Fullerenes; Glioblastoma; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Mice, Nude; Nanotechnology; Neoplasm Transplantation; Radioisotopes; Radionuclide Imaging

2011
Science to practice: can theranostic fullerenes be used to treat brain tumors?
    Radiology, 2011, Volume: 261, Issue:1

    Topics: Animals; Brachytherapy; Brain Neoplasms; Fullerenes; Glioblastoma; Lutetium; Mice; Mice, Nude; Radioisotopes

2011
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
    Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:2

    Topics: Animals; Cell Line, Tumor; Chelating Agents; Drug Evaluation, Preclinical; Epidermal Growth Factor; Glioblastoma; Humans; Lutetium; Mice; Mice, Inbred Strains; Pentetic Acid; Protein Binding; Radioisotopes; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution

2004